Download A4Medicine Mobile App
Empower Your RCGP AKT Journey: Master the MCQs with Us! 🚀
The National Institute for Health and Care Excellence (NICE) has recently updated its guidelines on the management of cardiovascular disease (CVD). This extensive revision reflects the evolving landscape of CVD management, integrating new evidence and practices to enhance patient care. The update encompasses various areas, including the utilization of statins for both primary and secondary prevention, approaches for individuals unable to tolerate statins, dietary recommendations, and strategies for assessing treatment responses. A notable aspect of this update is its emphasis on personalized care, cost-effectiveness, and a more nuanced approach to treatment, catering to the specific needs and circumstances of each patient.
| Area of Update | Key Changes and LDL Targets |
|---|---|
| Statins for Primary Prevention | • Focus on high-intensity statins. • Retention of 10% QRISK score threshold. • Personalized approach with atorvastatin 20 mg irrespective of QRISK3 score. |
| Statins for Secondary Prevention | • Consistent use of high-intensity statins. • LDL cholesterol target of >2.2 mmol/L for treatment escalation, with 2.0 mmol/L considered cost-effective. • Non-HDL cholesterol target set at 2.6 mmol/L. |
| Treatment for Statin Intolerance | • Ezetimibe recommended as the first alternative. • Additional treatments if ezetimibe... |
Try our Free Plan to get the full article.
